tirzepatide surpass cvot SURPASS-CVOT: better than dulagluti In patients with type 2

What CMS is planning to do Through the BALANCE Model, CMS plans to: Work with voluntary GLP-1 manufacturers to establish pricing and access terms Create a standardized pathway for participating Medicaid programs and Medicare plans to cover these medications Pair medication access with lifestyle and nutrition supports grounded in current scientific evidence Evaluate how the model affects access to care, health outcomes, costs and peoples experiences Key dates to know What we dont know yet Several important details have not been finalized, including: When beneficiaries will know whether their state Medicaid program or Medicare plan is participating What the enrollment process will look like The exact clinical criteria for individual eligibility to the programs What lifestyle and nutrition supports will be offered Whether lifestyle and nutrition supports will differ by drug manufacturer Because participation is voluntary for manufacturers and plans, we dont know how many people will participate in the programs An important first step Most people living with obesity who rely on Medicare or Medicaid face barriers to accessing obesity treatments

March 29 Product: Gileads Vemlidy Indication: Chronic hepatitis B in pediatric patients Gilead has scored a label extension for its antiviral Vemlidy, which is now available for pediatric patients ages six and older with chronic hepatitis B virus (HBV) with compensated liver disease who weigh at least 25 kg

Providers who proactively communicate about FDA guidance changes, explain how those changes affect their patients, and have contingency plans for supply disruptions earn trust that fair-weather providers lose when the regulatory landscape shifts

Grapefruit: Grapefruit products may increase Tadalafil blood levels and side effect risks

The unique glucagon receptor component that drives liver fat reduction and potentially increased energy expenditure